Fuad El-Hibri Wire

Mr. Fuad El-Hibri named Ernst & Young Entrepreneur of the Year 2009 award finalist in greater Washington

ROCKVILLE, Md. – (BUSINESS WIRE) – Emergent BioSolutions Inc. (NYSE:EBS) announced today that its chairman and chief executive officer, Mr. Fuad El-Hibri, is a finalist for the Ernst & Young Entrepreneur of the Year 2009 Award in the Greater Washington region. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mr. El-Hibri was selected as a finalist from nearly 100 nominations by a panel of independent judges. Award winners will be announced at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is an honor to be chosen as a finalist for the Ernst & Young Entrepreneur of the Year Award,” said Mr. Fuad El-Hibri. “I am proud of the entrepreneurial spirit, commitment, and collaboration that prevail at Emergent, which are key factors to our company’s success. This recognition represents the contributions of each and every member of the Emergent Team as we work together in pursuit of our company mission – to protect life.”

Mr. El-Hibri was also a finalist for the Greater Washington region in 2007. The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax. Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year Awards Program

Ernst & Young’s Entrepreneur of the Year Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Comment on this story, by email comment@newsblaze.com

Fuad El-Hibri	Margaret Hamburg	James Philips

“As we continue working toward our goal of an institution that will serve as a global information platform, we celebrate the election of three new board members who have each made key contributions to the creation of a healthier and safer world,” said Sullivan.

“Through his leadership in the field of biotechnology, Fuad El-Hibri is helping develop strategies to address serious threats to global health security.  Throughout a distinguished career in public service, Peggy Hamburg has focused her considerable intellect and medical training on similar concerns as well as a range of other pressing health policy issues.  And from his position at the vanguard of the information technology revolution, Jim Phillips has helped successfully launch companies and institutions that are improving our ability to connect, communicate and heal.

“We are proud to have earned the active interest and support of Fuad, Peggy and Jim and look forward to drawing extensively upon their experience and expertise as our efforts to develop NHM proceed,” said Sullivan.

Fuad El-Hibri, CEO and Chairman, Emergent Biosolutions

Fuad El-Hibri leads Emergent Biosolutions, a Maryland-based biotechnology company focused on the development, manufacture and commercialization of immunobiotics.  The company operates in two business segments: biodefense and commercial. In its biodefense business, Emergent develops and commercializes immunobiotics for use against biological agents that are potential weapons of bioterrorism. In its commercial business, the company develops immunobiotics for use against infectious diseases with significant unmet or underserved medical needs.

El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from 1998 until 2004, when BioPort became a subsidiary of Emergent.  He also served as chairman of Digicel Holdings, Ltd., a privately held cellular telecommunications firm, from August 2000 to October 2006.  Since 1990, he has also served as chairman of East West Resources Corporation, a venture capital and financial consulting firm.

He is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation which has contributed to a variety of international development projects, including a children’s orphanage in Lebanon.  He holds a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.

Margaret A. Hamburg, MD, Senior Scientist, Global Health and Security Initiative, NTI

One of the youngest people ever elected to the Institute of Medicine of the National Academy of Sciences, Dr. Margaret “Peggy” Hamburg is a highly regarded expert in community health and bio-defense, including preparedness for nuclear, biological, and chemical threats.  She currently serves as Senior Scientist for the Global Health and Security Initiative of the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons.  A graduate of Radcliffe College, she earned her M.D. from Harvard Medical School, and completed her training at the New York Hospital/Cornell University Medical Center.

From 1997 to 2001, Hamburg held the position of Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services (HHS), serving as principal policy advisor to Secretary of Health and Human Services Donna Shalala.  From 1991 to 1997, she served as New York City Health Commissioner, a position in which she designed and implemented an internationally recognized tuberculosis control program that produced dramatic declines in tuberculosis cases, and created the first public health bio-terrorism preparedness program in the nation.  Between 1986 and 1990, she held a variety of positions within HHS, including Special Assistant to the Director, Office of Disease Prevention and Health Promotion; and Special Assistant to the Director, and later Assistant Director, of the National Institute of Allergy & Infectious Diseases at the National Institutes of Health.

A member of the Harvard College Board of Overseers and the Boards of Trustees of Rockefeller University and the Rockefeller Foundation, Hamburg is also a distinguished senior fellow with the Center for Strategic and International Studies, and a fellow of the American Association of the Advancement of Science.  She holds membership in the New York Academy of Medicine, and the Council on Foreign Relations and serves on the board of Henry Schein Company.  She has served on the boards of other organizations, including the New York City Health and Hospitals Corporation, the Nathan Cummings Foundation, the Primary Care Development Corporation, and the Board of Scientific Counselors for the National Center for Infectious Diseases of the Centers for Disease Control and Prevention.

James M. Phillips, Vice Chairman, Luminetx

James “Jim” Phillips’s career has been marked by success at starting and guiding companies through successful initial public offerings and pioneering new technologies into major industry-leading positions – including the PDA, digital cell phone, fixed cellular and internet multimedia.  A classic entrepreneur, Phillips’ began his career with Telecommunications System of America, which was sold to Northern Telecom (Nortel), where Phillips eventually became vice president.  He held subsequent executive positions at SkyTel, which became the nation’s largest messaging company; Telular Corporation, the world’s largest fixed wireless cellular company; and Motorola, where he participated in launching digital cellular and multimedia, bringing cable modem to the market.

Phillips then became Chairman and CEO of IPIX, which produced digital photographs with 360° navigable images that are today widely used on major Web sites.  After taking the company public, he was asked to become involved with the effort to build the FedEx Institute of Technology (FIT), a partnership between Federal Express Corp. and The University of Memphis.  Phillips resigned from IPIX, moved to Memphis and raised $100 million to make FIT a reality.  Information Week has called FIT the technology industry’s “newest center for innovation” and WIRED has compared it to the famous Media Lab at MIT.

After successfully launching FIT, Phillips served as CEO in residence at Morgan Keegan, a Memphis-based investment firm, before raising the capital to launch Luminetx Corporation.  Luminetx produces the VeinViewer, which was named in 2004 by Time as “one of the coolest medical inventions of the year.”  Phillips is Vice Chairman of Luminetx, having previously served as the company’s CEO, president and chairman.  A holder of patents in cell phone, PDA and data modem design, he also serves on a number of boards including the American Museum of Science and Energy, Visio Technologies Corporation, EmergeMemphis, Memphis Biotech Foundation, University of Memphis Fogelman School of Business and Economics, and the Memphis Area Chamber of Commerce.

Fuad El-Hibri, MBA
Chief Executive Officer and Chairman of the Board of Directors
Emergent Biosolutions, Inc.
Yale School of Management

Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University.

ROCKVILLE, Md.–(Business Wire)– Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.

As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and managing Emergent’s scientific advisory board. Additionally, Dr. Jackson will support the CEO in external communications by providing scientific expertise and perspective about the company’s technologies, platforms, and product candidates to government agencies and officials, investors, analysts and at scientific meetings.

“I am honored to be named chief scientific officer of Emergent BioSolutions. Because we are such a pioneering and growth-oriented company, I look forward to playing a leading role in the company’s new product acquisition efforts, and to applying my experience to help extend the company’s product portfolio in pursuit of our strategic goals,” said Dr. Jackson.

Dr. Jackson joined Emergent BioSolutions in 2003, as a result of Emergent’s acquisition of Antex Biologics Inc., where Dr. Jackson had been vice president of research and development. Since 2003, Dr. Jackson has served in several management capacities within the company including vice president, commercial product development and most recently as vice president, technical support. Dr. Jackson brings over 20 years of biopharmaceutical research and development experience to the company, including leading research efforts related to antigen identification and characterization, pre-clinical evaluation, and initial development of bacterial vaccines in the areas of respiratory, enteric, and sexually transmitted diseases. Among his accomplishments, Dr. Jackson has been issued 17 U.S. and foreign patents, obtained a number of state and federal research grants and has published frequently in various scientific journals. Dr. Jackson holds a Ph.D. in microbiology from the University of Georgia.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a profitable, multinational biopharmaceutical company dedicated to one simple mission — to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. More information on the company is available at www.emergentbiosolutions.com.

Emergent BioSolutions Inc.
Investors:
Robert G. Burrows, 301-795-1877
Vice President, Investor Relations
BurrowsR@ebsi.com
or
Media:
Tracey Schmitt, 301-795-1800
Director, Corporate Communications
SchmittT@ebsi.com

Copyright Business Wire 2008

Emergent BioSolutions Inc. announced that the Drugs Controller General of India (DCGI) has issued a registration certificate for BioThrax (Anthrax Vaccine Adsorbed), which enables the marketing and sale of the vaccine in India to help prevent anthrax infection.

Fuad El-Hibri’s Emergent BioSolutions gets market authorization in India for BioThrax

According to a release, Emergent BioSolutions has signed a marketing agreement with Biological E. Limited for the marketing of BioThrax in India. BioThrax is the only vaccine for the prevention of anthrax infection licensed by the U.S. Food and Drug Administration (FDA).

The company noted that the BioThrax market authorization for India follows the publication in 2008 of the National Disaster Management Guidelines by the Indian National Disaster Management Authority (NDMA), which is the government body that oversees disaster management. In that document, the  government of India provided guidance with respect to the management of biological disasters and said that there is a need to have a supply of readily available anthrax vaccines to be administered rapidly in the event of an outbreak. The report goes on to state that all first responders will be vaccinated in an impending disaster situation.

Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, said, “The Government of India has been explicit in expressing its commitment to protect its population from the continuing threat of bioterrorism. We are certainly pleased that BioThrax will be a valuable countermeasure available to the Government of India to achieve that goal. Today marks a pivotal milestone in Emergent’s efforts to expand globally and further our mission of protecting life.”

About BioThrax (Anthrax Vaccine Adsorbed): BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is licensed by the FDA as a pre-exposure prophylaxis for use in adults who are at high risk of exposure to anthrax spores. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis and contains no dead or live bacteria. Since 1998, the U.S. government has procured nearly 33.5 million doses of BioThrax. During that time period, nearly 8.4  million doses have been administered to more than 2.1 million military personnel. BioThrax cannot cause anthrax infection. Please visit emergentbiosolutions.com/pdf/emergent_biothrax_us.pdf for full prescribing information.

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immune-related biologic products, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Emergent BioSolutions Inc (EBS) click here. Emergent BioSolutions Inc (EBS) has Short Term PowerRatings of 1. Details on Emergent BioSolutions Inc (EBS) Short Term PowerRatings is available at This Link.

Posted in BioThrax, El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: Bacillus anthracis, BioThrax, Emergent BioSolutions, Government of India, India, United States, US Food and Drug Administration, Vaccine

Fuad El-Hibri and Emergent BioSolutions are handing our bonuses

Fuad El-Hibri and Emergent BioSolutions are handing our bonuses

Bonus may be a bad word right now — but not for a biotech that is actually making money.

Alongside minimal pay raises, Emergent BioSolutions Inc. execs received bonuses in 2008 that increased anywhere from 5 percent to 43 percent from their 2007 bonuses. Fuad El-Hibri, chief executive officer and chairman of the Rockville company, got the lowest increase, but the highest bonus at $323,250. The highest increase was doled out to Kyle Keese, senior vice president of manufacturing operations, who took home a $96,460 bonus for 2008.

Though, at least one manager’s perk wasn’t quite so perky last year. Robert Kramer, who stepped down in January as head of Emergent’s manufacturing subsidiary and instead will manage a contract that the company hopes to nail with the federal government this year, got a 48 percent decrease in his bonus from 2007, bringing his 2008 figure to $78,815.

While Emergent is one of the few biotechs netting a profit, its numbers did dip slightly from 2007 to 2008 — by 2 percent of revenue and 10 percent of profits — because of fewer or delayed shipments of its anthrax vaccine to the federal government. But whereas other biotechs have been shaving down their work forces, Emergent added people in 2008, up to 587 people from 560 in 2007.

---

Posted in El-Hibri Fuad, Emergent BioSolutions, Emergent BioSolutions Inc, Fuad El-Hibri
Tags: Chief executive officer, Emergent BioSolutions, Executive, Manufacturing, Manufacturing operations, Rockville, United States, Vice president

Posted in El-Hibri Fuad, Fuad El-Hibri, Yale School of Management
Tags: Class reunion, Education, High school, Michael Dowling, Military, REUNION, United States, Veterans

Fuad El-Hibri at Yale School of Management